Prognostic role of metformin in diabetes mellitus type 2 patients with hepatocellular carcinoma: A systematic review and meta-analysis

Table 2 Characteristics of included studies for the risk of progressive tumor disease

Ref.	City	Country	Study period	Design	N	Therapy	DM (no metformin)	Number of events	DM (metformin)	Number of events
Jang et al[30], 2015	Seoul	Korea	March 2003 to December 2012	Retro	48	RT	29	24	19	9
Casadei Gardini et al[31], 2015	Meldola	Italy	March 2008 to August 2014	Retro	42	Sorafenib	11	9	31	28
Casadei Gardini et al[24], 2017	Meldola	Italy	May 2007 to September 2015	Retro	86	Sorafenib	34	33	52	47
Chung et al[34], 2018	Seoul	Korea	January 2009 to December 2016	Retro	63	Sorafenib + HR	23	23	40	40
					31	Sorafenib + LT	17	17	14	14
Total					270		114	106	156	138

DM: Diabetes mellitus; Retro: Retrospective; RT: Radiotherapy; HR: Hepatic resection; LT: Liver transplantation.